Delivery Order SPE2DB22D9311-SPE2DB25FP6ZN
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $17,022.00 firm fixed-price delivery order is for the supply of 4568292980 BOOSTRIX TDAP VACCINE SYRINGE 0.5ML, with a period of performance through May 14, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
- This is a $28,696.68 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the BOOSTRIX TDAP vaccine syringe, 0.5 mL, with a completion date of June 14, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $6,815.90 firm fixed-price contract is for the procurement of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML, a pharmaceutical product, with a period of performance ending on January 17, 2025. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, enabling the...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,807.60 firm fixed-price contract is for the supply of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue...
- This federal contract award is for the delivery of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML to the Defense Logistics Agency (DLA). The $6,535.22 firm fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has an ultimate completion date of May 13, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
- This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract, valued at $7,387.64, is for the delivery of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML. The contract has a performance period through April 28, 2025 and is a firm fixed-price delivery order. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business located in Park Ridge, Illinois. The contract, valued at $2,062.24, is for the delivery of Boostrix TDAP vaccine syringes. The award has no set-aside designation and is part of a larger $4,999,999 indefinite delivery vehicle (IDV) that DMS Pharmaceutical Group holds with DLA to provide a broad range of pharmaceutical items...
- This is a federal contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,830.38 firm fixed-price delivery order is for the supply of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML, with a performance period ending on June 13, 2025. The contract is not designated as a set-aside. DMS Pharmaceutical Group has a significant $499,999,999 Indefinite Delivery Contract (IDC) with DLA under...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $28,076.00, is a firm fixed-price delivery order for BOOSTRIX TDAP VACCINE SYRINGE 0.5ML. The award is not associated with a set-aside designation. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
- This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is a $3,145.80 firm fixed-price delivery order for the supply of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML, a specialized pharmaceutical product. The contract has an ultimate completion date of January 22, 2025 and was awarded on January 21, 2025. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery...
- SPE2DB22D9311Indefinite Delivery Contract
- SPE2DB22D9311-SPE2DB25FP6ZNDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Boostrix TDAP vaccine syringes (0.5mL) under a firm fixed-price contract. This delivery order, valued at $13,922.86 with an ultimate completion date of July 21, 2025, was issued without a set-aside designation. The award leverages DMS Pharmaceutical Group's position as a critical supplier within the federal pharmaceutical supply chain, supported by the company's established expertise in distributing medical supplies and medications to Department of Defense healthcare facilities. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. The IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including vaccines, biologics, prescription drugs, and medical consumables to support military health facilities worldwide. DMS Pharmaceutical Group's consistent success in securing federal pharmaceutical contracts demonstrates its capability to effectively compete in defense procurement markets and maintain a robust distribution portfolio serving military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.9k | 7/18/25 |